Mednet Logo
SpecialtiesPulmonology
Pulmonology

Pulmonology

Physician discussions on respiratory conditions, critical care, interstitial lung disease, and pulmonary procedures.

Recent Discussions

How do you counsel patients who are concerned that discontinuation of certain chronic medications may actually perpetuate suffering at the end of life?

3
1 Answers

Mednet Member
Mednet Member
Geriatric Medicine · Icahn School of Medicine at Mount Sinai

Great question, and it’s very nuanced. I’ll share how I typically approach this based on my experience. In the end-of-life care setting, when I review a medication list, I go through every single one and ask: “What is the purpose of this medication in this particular case?” For example, anticoagul...

How do you titrate opioids for pain and breathlessness in patients with a DNR/DNI code status, but who otherwise still wish to pursue life-prolonging treatments?

1
2 Answers

Mednet Member
Mednet Member
Hospital Medicine · University of Tennessee Health Science Center

Carefully! But let's be very clear about this situation: the DNR/DNI status shouldn't really affect your management if the patient wants full treatment otherwise. In fact, even if someone opts for a hospice care plan and does not want full treatment nor resuscitation, we can still have the same gene...

What are your top takeaways from ATS 2026?

1 Answers

Mednet Member
Mednet Member
Pulmonology · University of Chicago

I was impressed with the FROSTBITE-2 study published in JAMA!It was a well-designed study and supports the use of a 1.1 mm cryoprobe in many bronchoscopic lung biopsy settings. This is a practice-changing level of evidence for bronchoscopists and will help us get better results for our patients.

Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Fox Chase Cancer Center

This is a good question! The short answer is yes, most likely. Many patients are too high-risk to receive biopsies; this is decided by surgery/pulm/IR. Unless the patient has contraindications to RT or something like severe IPF (where treatment may be worse than the disease), I would likely offer th...

In cirrhosis patients with borderline pre-transplant PVR (≈2–3 WU), what additional findings (e.g., mPAP/TPG, pulmonary artery compliance, RV strain on echo, DLCO) prompt you to treat this as higher risk and arrange closer follow-up or PH-center referral rather than reassuring the transplant team?

1 Answers

Mednet Member
Mednet Member
Pulmonology · Mayo Clinic Pulmonary Medicine

Agree that recent data do suggest that pulmonary vascular resistance (PVR) 2 to 3 Wood units should be followed carefully in patients who are liver transplant candidates.Using historical data and International Liver Transplant Society (ILTS) Guidelines, mean pulmonary arterial pressure (mPAP) < 35 m...

How would you manage a patient with necrotizing pneumonia due to a susceptible Pseudomonas aeruginosa strain who continues to have significant purulent secretions and worsening imaging while receiving cefepime?

1
3 Answers

Mednet Member
Mednet Member
Pulmonology · NYU Langone Pulmonary Associates

I agree, not enough information here to make a firm recommendation, but often times these necrotic pneumonias will undergo significant liquefactive necrosis, and all of that dead lung and purulence has to come out through the mouth. I tell patients that they may have a worse cough for a while, and t...

What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?

2
2 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

The available literature on abatacept and tocilizumab in RA-ILD does not provide a definitive answer and hopefully with the general increase in interest in ILD we will have more definitive data in the near future. My review of the current literature suggests that abatacept has a slightly higher perc...

For locally advanced NSCLC, does endobronchial tumor debulking just prior to treatment influence your decision making regarding bronchial tissue constraints/expected toxicity?

3
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Quillen VA Medical Center

Bulky, large endobronchial lesions both bleed and obstruct. The concern should be the length and depth of the tumor. If destruction of the trachea or bronchial tumor risks bleeding and B/P fistula, it may account for some of the hazards associated with “ultra-central” location. The endobronchial deb...

How do you manage a cytology-negative pleural effusion that develops after lung RT?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

I think most times you can just watch them as long as they are stable and not symptomatic. I see them not infrequently after RT, especially lung SBRT, and find they often find a size they feel comfortable with and don't change much over time. I wonder about their physiology... my impression is there...

How do you counsel eligible patients on lung cancer screening who are hesitant because of the cancer risk from CT scans?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · UCLA | VA Greater Los Angeles Healthcare System

This is simple. The risk of lung cancer in patients who have smoked for >20 years is orders of magnitude higher than the theoretical risk of medical X-ray-induced cancers from low-dose CT (LDCT) screening. A typical LDCT scan exposes patients to approximately 1.5 mSv of radiation, equivalent to abou...